Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 6/20 | 0.54 |
| ▸ | BRAF | P15056 | 10/20 | 0.48 |
| ▸ | KDR | P35968 | 4/20 | 0.48 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.48 |
| ▸ | FLT1 | P17948 | 3/20 | 0.48 |
| ▸ | LCK | P06239 | 2/20 | 0.48 |
| ▸ | FYN | P06241 | 2/20 | 0.48 |
| ▸ | KIT | P10721 | 2/20 | 0.48 |
| ▸ | FLT4 | P35916 | 2/20 | 0.48 |
| ▸ | SRC | P12931 | 1/20 | 0.48 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.43 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.43 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.43 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.43 |
| ▸ | RAF1 | P04049 | 2/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5436373 | 0.94 | MAPK14 (0.47) | FGFR1BRAFKDRPDGFRBFLT1 | |
| SCHEMBL545450 | 0.86 | BRAF (0.50) | FGFR1BRAFKDRPDGFRBFLT1 | |
| SCHEMBL5418775 | 0.84 | BRAF (0.52) | FGFR1BRAFKDRPDGFRBFLT1 | |
| SCHEMBL10200809 | 0.84 | BRAF (0.51) | BRAFKDRPDGFRBFLT1LCK | |
| SCHEMBL545071 | 0.83 | BRAF (0.50) | FGFR1BRAFKDRPDGFRBFLT1 | |
| SCHEMBL5423590 | 0.83 | BRAF (0.62) | BRAFKDRPDGFRBFLT1LCK | |
| SCHEMBL4643326 | 0.83 | BRAF (0.54) | BRAFKDRPDGFRBFLT1LCK | |
| SCHEMBL545127 | 0.83 | BRAF (0.54) | FGFR1BRAFKDRPDGFRBFLT1 | |
| SCHEMBL545264 | 0.82 | BRAF (0.51) | BRAFKDRPDGFRBFLT1LCK | |
| SCHEMBL544977 | 0.81 | BRAF (0.51) | BRAFKDRPDGFRBFLT1LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8110687-B2 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-02-07 | — | — | US | disclosed |
| US-20070149533-A1 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149533-A1 | Bicyclic compounds with kinase inhibitory activity | MAP3K20, MAP3K1, MAP3K5 | FGFR1 580/4885BRAF 215/4885KDR 1264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.